December 19, 2023 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction 17 million people in the U.S. have confirmed... Read more

December 5, 2023 Bio/Pharma/CRO

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting... Read more

October 31, 2023 Bio/Pharma/CRO Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

WASHINGTON, Oct. 31, 2023 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024. Mr. Riley, currently Vice President and... Read more

June 30, 2023 Bio/Pharma/CRO Informatics & Software Lab Top-10

Bruker Announces SciY™ Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

ZUERICH, Switzerland–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the SciY™ platform of advanced, vendor-agnostic software solutions for data analysis, data management, research lab and bioproduction QC digitalization, and workflow automation in the life science industry and for biopharma companies. The new SciY platform combines and integrates high-performance lab software solutions for a more comprehensive,... Read more

January 4, 2023 Bio/Pharma/CRO Lab Top-10 Licensing, IP, and Legal Liq. Handling & Robotics M&A, Partnerships Other Lab Products/Services

Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics Expected to benefit proteomics research, disease biomarker discovery, drug discovery and development, and clinical trials leveraging pharmacoproteomics With Bruker investments, Biognosys plans to open advanced US proteomics CRO facility for proteomics biomarker and drug... Read more